TrialBMC gastroenterology2023

Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn's disease.

Silvio Danese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.